What does this research mean for the field?

Distinct metabolic signatures and novel biomarkers, including specific carbohydrates, fatty acids, and amino acid metabolites, differentiate genetic subtypes of methylmalonic acidemia (MUT-MMA vs. CblC-MMA) and their specific clinical presentations. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Investigate comprehensive metabolic remodeling signatures and biomarker profiles across different genetic subtypes and clinical presentations of methylmalonic acidemia before and after treatment.

September 8, 2026ACS OmegaOpen Access

Exploration of Metabolic Alterations in Methylmalonic Acidemia across Distinct Genetic Backgrounds

View Full Paper

Ask AI

Bookmark

Authors

HZHaijuan ZhiShanghai Jiao Tong University YDYi DingSouthwest Petroleum University YDYu-Xin DengShanghai Jiao Tong University

Discussion

Member takes

Implication

Cohort study reveals subtype-specific metabolic remodeling and clinical biomarkers in methylmalonic acidemia, highlighting pathways for precise diagnosis and therapeutic monitoring.

Key Points

Investigate comprehensive metabolic remodeling signatures and biomarker profiles across different genetic subtypes and clinical presentations of methylmalonic acidemia before and after treatment.
Conducted targeted metabolomics on dried blood spot samples from a Chinese cohort of 85 patients, comprising 42 with MUT-MMA, 23 with CblC-MMA, and 20 with CblC-MMA presenting with kidney injury and pulmonary arterial hypertension.
Assessed post-treatment metabolite alterations using reduction analysis to track treatment-associated metabolic changes.
Identified subtype-specific metabolic shifts, highlighting carbohydrates and short-chain fatty acids as biomarkers for MUT-MMA, alongside altered unsaturated fatty acids and aromatic amino acid biosynthesis pathways in CblC-MMA.
Characterized distinct metabolic remodeling patterns following clinical treatment across patient subgroups.
Identified phenylacetylglutamine and isovalerylcarnitine as discriminatory biomarkers separating CblC-MMA patients with kidney injury and pulmonary arterial hypertension from other presentations.

Cite This Study

Zhi et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd7ab58e84d0ff5b468d6 https://doi.org/10.1021/acsomega.6c06980

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals subtype-specific metabolic remodeling and clinical biomarkers in methylmalonic acidemia, highlighting pathways for precise diagnosis and therapeutic monitoring.

Exploration of Metabolic Alterations in Methylmalonic Acidemia across Distinct Genetic Backgrounds

Discussion

Member takes

Implication

Key Points

Cite This Study

Exploration of Metabolic Alterations in Methylmalonic Acidemia across Distinct Genetic Backgrounds

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider